Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
regenerative medicine
Biotech
Aspen adds $115M series C to grow cell therapy ambitions
The raise will power Aspen’s phase 1/2 study of ANPD001, a regenerative cell therapy for Parkinson's disease.
Darren Incorvaia
Nov 20, 2025 7:02am
Precise Bio completes 1st 3D-printed human cornea transplant
Nov 19, 2025 8:30am
Pelage locks in $120M series B for hair growth program
Oct 15, 2025 7:00am
Pfizer vet takes CEO post at new, phase 3-ready biotech
Sep 9, 2025 10:03am
FDA approves Humacyte’s off-the-shelf artery for trauma repairs
Dec 23, 2024 10:36am
Aurion's regenerative med improves vision in phase 1/2 trial
Dec 18, 2024 7:00am
